GleamWall
中文EN

CGEM Cullinan Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1789972 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY6.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-55.5%
ROA-50.4%
ROIC (approx.)-63.9%
Asset turnover—

Leverage & solvency

Liabilities / assets12.8%
Debt / equity0.00x
Current ratio7.43x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.81x
Accruals ratio-9.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$187.40M$142.90M
SG&A expense$54.25M$54.02M
Operating income-$241.65M-$196.92M
Pretax income-$219.88M-$167.46M
Income tax$0$117,000
Net income-$219.88M-$167.38M
EBITDA-$241.34M-$196.61M
EPS (diluted)——
Balance sheet
Cash & equivalents$88.33M$83.00M
Short-term investments$289.56M$315.97M
Current assets$386.76M$414.67M
PP&E, net$421,000$683,000
Total assets$448.37M$621.82M
Current liabilities$37.74M$30.65M
Total liabilities$39.64M$31.50M
Shareholders' equity$408.73M$590.33M
Shares outstanding60.24M58.51M
Cash flow statement
Operating cash flow-$175.75M-$145.30M
Capital expenditure$49,000$0
Free cash flow-$175.80M-$145.30M
Investing cash flow$179.99M-$136.31M
Financing cash flow$1.09M$266.19M
Depreciation & amortization$311,000$306,000
Stock-based compensation$36.04M$37.82M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.